Macitentan and tadalafil as a fixed-dose combination (FDC) is in clinical development for the
treatment of pulmonary arterial hypertension (PAH). PAH is a rare disorder in which there is
severe narrowing of the arteries of the lungs. More pressure is needed to force blood through the
narrowed artery which this leads to high blood pressure in the lungs
Macitentan-tadalafil for treating pulmonary arterial hypertension
Macitentan and tadalafil as a fixed-dose combination (FDC) is in clinical development for the treatment of pulmonary arterial hypertension (PAH).
Interventions:
Macitentan-tadalafil
Indications:
Pulmonary arterial hypertension (PAH)
Year:
2022